|
US7935812B2
(en)
|
2002-02-20 |
2011-05-03 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
|
ATE485031T1
(de)
|
2002-06-28 |
2010-11-15 |
Protiva Biotherapeutics Inc |
Verfahren und vorrichtung zur herstellung von liposomen
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
ES2559828T3
(es)
*
|
2003-07-16 |
2016-02-16 |
Protiva Biotherapeutics Inc. |
ARN de interferencia encapsulado en lípidos
|
|
AU2004272646B2
(en)
*
|
2003-09-15 |
2011-11-24 |
Arbutus Biopharma Corporation |
Polyethyleneglycol-modified lipid compounds and uses thereof
|
|
WO2005060697A2
(en)
*
|
2003-12-19 |
2005-07-07 |
Chiron Corporation |
Cell transfecting formulations of small interfering rna, related compositions and methods of making and use
|
|
EP2636739B1
(en)
|
2004-03-12 |
2014-12-10 |
Alnylam Pharmaceuticals Inc. |
iRNA agents targeting VEGF
|
|
MXPA06012076A
(es)
*
|
2004-04-20 |
2007-01-25 |
Nastech Pharm Co |
Metodos y composiciones para mejorar el suministro de arn bicatenario o un acido nucleico hibrido bicatenario para regular la expresion genetica en celulas de mamifero.
|
|
US20060040882A1
(en)
*
|
2004-05-04 |
2006-02-23 |
Lishan Chen |
Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
|
|
EP1781593B1
(en)
|
2004-06-07 |
2011-12-14 |
Protiva Biotherapeutics Inc. |
Cationic lipids and methods of use
|
|
EP1766035B1
(en)
|
2004-06-07 |
2011-12-07 |
Protiva Biotherapeutics Inc. |
Lipid encapsulated interfering rna
|
|
EP1773857A4
(en)
|
2004-07-02 |
2009-05-13 |
Protiva Biotherapeutics Inc |
THE IMMUNE SYSTEM STIMULATING SIRNA MOLECULES AND APPLICATIONS THEREOF
|
|
WO2006020182A2
(en)
*
|
2004-07-16 |
2006-02-23 |
Smart Medical Technologies, Llc |
Centrifuge system
|
|
GB0418172D0
(en)
*
|
2004-08-13 |
2004-09-15 |
Ic Vec Ltd |
Vector
|
|
JP2008509205A
(ja)
*
|
2004-08-13 |
2008-03-27 |
アイシー・ベック・リミテッド |
ポリマー修飾ｓｉＲＮＡリポソームを含むベクター
|
|
JP5101288B2
(ja)
|
2004-10-05 |
2012-12-19 |
カリフォルニア インスティテュート オブ テクノロジー |
アプタマー調節される核酸及びその利用
|
|
WO2007001448A2
(en)
|
2004-11-04 |
2007-01-04 |
Massachusetts Institute Of Technology |
Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
|
|
AU2005306533B2
(en)
*
|
2004-11-17 |
2012-05-31 |
Arbutus Biopharma Corporation |
siRNA silencing of apolipoprotein B
|
|
US9393315B2
(en)
|
2011-06-08 |
2016-07-19 |
Nitto Denko Corporation |
Compounds for targeting drug delivery and enhancing siRNA activity
|
|
WO2006074546A1
(en)
*
|
2005-01-13 |
2006-07-20 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
|
WO2007086883A2
(en)
*
|
2005-02-14 |
2007-08-02 |
Sirna Therapeutics, Inc. |
Cationic lipids and formulated molecular compositions containing them
|
|
US20070213293A1
(en)
*
|
2005-04-08 |
2007-09-13 |
Nastech Pharmaceutical Company Inc. |
Rnai therapeutic for respiratory virus infection
|
|
JP2008536874A
(ja)
*
|
2005-04-15 |
2008-09-11 |
ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム |
中性脂質組成物によるｓｉＲＮＡの送達
|
|
US9095630B2
(en)
|
2005-05-19 |
2015-08-04 |
L'oreal |
Vectorization of dsRNA by cationic particles and use of same on a skin model
|
|
FR2885813B1
(fr)
*
|
2005-05-19 |
2008-01-11 |
Oreal |
Vectorisation de dsrna par des particules cationiques et leur utilisation sur modele de peau.
|
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
|
JP5571308B2
(ja)
*
|
2005-09-15 |
2014-08-13 |
マリーナ バイオテック，インコーポレイテッド |
両性リポソームにおけるまたはそれに関する改善
|
|
TW200800235A
(en)
*
|
2005-10-18 |
2008-01-01 |
Otsuka Pharma Co Ltd |
Carrier composition for nucleic acid transport
|
|
WO2007048046A2
(en)
*
|
2005-10-20 |
2007-04-26 |
Protiva Biotherapeutics, Inc. |
Sirna silencing of filovirus gene expression
|
|
CA2628300C
(en)
|
2005-11-02 |
2018-04-17 |
Protiva Biotherapeutics, Inc. |
Modified sirna molecules and uses thereof
|
|
US9267937B2
(en)
|
2005-12-15 |
2016-02-23 |
Massachusetts Institute Of Technology |
System for screening particles
|
|
JP2009534309A
(ja)
|
2006-03-31 |
2009-09-24 |
マサチューセッツ インスティテュート オブ テクノロジー |
治療剤の標的化送達のためのシステム
|
|
WO2007134161A2
(en)
|
2006-05-11 |
2007-11-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the pcsk9 gene
|
|
EP2019691B1
(en)
|
2006-05-15 |
2020-08-12 |
Massachusetts Institute of Technology |
Polymers for functional particles
|
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
US7915399B2
(en)
*
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
US9381477B2
(en)
|
2006-06-23 |
2016-07-05 |
Massachusetts Institute Of Technology |
Microfluidic synthesis of organic nanoparticles
|
|
AU2007284036A1
(en)
*
|
2006-08-16 |
2008-02-21 |
Protiva Biotherapeutics, Inc. |
Nucleic acid modulation of Toll-like receptor-mediated immune stimulation
|
|
CA2661292A1
(en)
*
|
2006-08-24 |
2008-02-28 |
British Columbia Cancer Agency Branch |
Compositions and methods for treating myelosuppression
|
|
MX2009003548A
(es)
|
2006-10-03 |
2009-04-15 |
Alnylam Pharmaceuticals Inc |
Formulaciones que contienen lipidos.
|
|
AU2014200915A1
(en)
*
|
2006-10-03 |
2014-03-13 |
Tekmira Pharmaceuticals Corporation |
Lipid containing formulations
|
|
WO2008058291A2
(en)
|
2006-11-09 |
2008-05-15 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
|
CN102604951A
(zh)
*
|
2006-12-14 |
2012-07-25 |
诺瓦提斯公司 |
治疗肌肉和心血管病症的组合物和方法
|
|
WO2008074487A2
(en)
|
2006-12-19 |
2008-06-26 |
Novosom Ag |
Lipids and lipid assemblies comprising transfection enhancer elements
|
|
US7985058B2
(en)
*
|
2007-01-12 |
2011-07-26 |
Mark Gray |
Method and apparatus for making uniformly sized particles
|
|
US20080171078A1
(en)
*
|
2007-01-12 |
2008-07-17 |
Mark Gray |
Uniformly sized liposomes
|
|
WO2008097623A2
(en)
|
2007-02-07 |
2008-08-14 |
Gradalis, Inc. |
Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy
|
|
EP2134830A2
(en)
|
2007-02-09 |
2009-12-23 |
Massachusetts Institute of Technology |
Oscillating cell culture bioreactor
|
|
EP2131848A4
(en)
*
|
2007-02-16 |
2012-06-27 |
Merck Sharp & Dohme |
COMPOSITIONS AND METHODS FOR REINFORCED ACTIVITY OF BIOLOGICAL ACTIVE MOLECULES
|
|
US8067390B2
(en)
*
|
2007-03-02 |
2011-11-29 |
The Board Of Regents Of The University Of Texas System |
Therapeutic targeting of interleukins using siRNA in neutral liposomes
|
|
TWI428135B
(zh)
*
|
2007-03-26 |
2014-03-01 |
Hirofumi Takeuchi |
And a carrier composition for quick-acting nucleic acid delivery
|
|
EP2144600A4
(en)
|
2007-04-04 |
2011-03-16 |
Massachusetts Inst Technology |
POLY (AMINIC ACID) TARGET MOLECULES
|
|
WO2008124634A1
(en)
*
|
2007-04-04 |
2008-10-16 |
Massachusetts Institute Of Technology |
Polymer-encapsulated reverse micelles
|
|
NZ580707A
(en)
|
2007-05-04 |
2011-11-25 |
Marina Biotech Inc |
Acylated cationic amino acids and uses thereof
|
|
CA2691840C
(en)
*
|
2007-06-29 |
2016-08-09 |
Statens Serum Institut |
The use of monomycolyl glycerol (mmg) as an adjuvant
|
|
WO2009011855A2
(en)
*
|
2007-07-16 |
2009-01-22 |
California Institute Of Technology |
Selection of nucleic acid-based sensor domains within nucleic acid switch platform
|
|
WO2009021325A1
(en)
|
2007-08-10 |
2009-02-19 |
British Columbia Cancer Agency Branch |
Microrna compositions and methods for the treatment of myelogenous leukemia
|
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
|
US8367815B2
(en)
*
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
|
US8865667B2
(en)
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
|
EP2620157A3
(en)
|
2007-10-12 |
2013-10-16 |
Massachusetts Institute of Technology |
Vaccine nanotechnology
|
|
US9029524B2
(en)
*
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
|
EP2617828B1
(en)
|
2007-12-10 |
2014-09-24 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
|
KR101590652B1
(ko)
*
|
2007-12-13 |
2016-02-18 |
뽈리쁠뤼스-트랑스펙씨옹 |
합성 중합체를 사용하여 유전자 사일런싱에 활성이 있는 핵산을 전달하기 위한 수단
|
|
ES2535419T3
(es)
*
|
2007-12-27 |
2015-05-11 |
Protiva Biotherapeutics Inc. |
Silenciamiento de expresión de quinasa tipo polo usando ARN interferente
|
|
JP2011511004A
(ja)
*
|
2008-01-31 |
2011-04-07 |
アルナイラム ファーマシューティカルズ インコーポレイテッド |
ＰＣＳＫ９遺伝子を標的とするｄｓＲＮＡを送達するための最適化された方法
|
|
BRPI0909779A2
(pt)
*
|
2008-03-05 |
2019-09-24 |
Alnylam Pharmaceuticals Inc |
composições e processos para a inibição da expressão dos genes eg5 e vegf
|
|
WO2009129319A2
(en)
|
2008-04-15 |
2009-10-22 |
Protiva Biotherapeutics, Inc. |
Silencing of csn5 gene expression using interfering rna
|
|
ES2638448T3
(es)
|
2008-04-15 |
2017-10-20 |
Protiva Biotherapeutics Inc. |
Novedosas formulaciones de lípidos para la administración de ácidos nucleicos
|
|
US8389768B2
(en)
*
|
2008-05-19 |
2013-03-05 |
The University Of North Carolina At Chapel Hill |
Methods and compositions comprising novel cationic lipids
|
|
CN102112110A
(zh)
*
|
2008-06-06 |
2011-06-29 |
米尔纳医疗股份有限公司 |
用于RNAi试剂体内递送的新型组合物
|
|
US8889640B1
(en)
*
|
2008-06-20 |
2014-11-18 |
Jill P. Smith |
Composition and method for the treatment of gastrin mediated cancers
|
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
|
US8034922B2
(en)
|
2008-08-22 |
2011-10-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for modulating activity of capped small RNAs
|
|
WO2010028054A1
(en)
|
2008-09-02 |
2010-03-11 |
Alnylam Europe Ag. |
Compositions and methods for inhibiting expression of mutant egfr gene
|
|
WO2010030730A1
(en)
*
|
2008-09-10 |
2010-03-18 |
Abbott Laboratories |
Polyethylene glycol lipid conjugates and uses thereof
|
|
CA2753338A1
(en)
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
|
EP3584320A1
(en)
|
2008-09-25 |
2019-12-25 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
|
EP2743265B1
(en)
|
2008-10-09 |
2017-03-15 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
AU2009302217A1
(en)
*
|
2008-10-09 |
2010-04-15 |
Northeastern University |
Multifunctional self-assembling polymeric nanosystems
|
|
US8591905B2
(en)
|
2008-10-12 |
2013-11-26 |
The Brigham And Women's Hospital, Inc. |
Nicotine immunonanotherapeutics
|
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
|
US8343498B2
(en)
|
2008-10-12 |
2013-01-01 |
Massachusetts Institute Of Technology |
Adjuvant incorporation in immunonanotherapeutics
|
|
US8277812B2
(en)
|
2008-10-12 |
2012-10-02 |
Massachusetts Institute Of Technology |
Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
|
|
CN104382853A
(zh)
|
2008-10-16 |
2015-03-04 |
玛瑞纳生物技术有限公司 |
基因沉默治疗剂的脂质体有效递送方法和组合物
|
|
PT2937418T
(pt)
*
|
2008-10-20 |
2018-01-23 |
Alnylam Pharmaceuticals Inc |
Composições e métodos de inibição da expressão de transtirretina
|
|
CN102203618B
(zh)
|
2008-10-30 |
2014-10-15 |
郭培宣 |
用于dna测序和其他用途的膜集成病毒dna包装马达蛋白连接器生物传感器
|
|
EA037404B1
(ru)
|
2008-11-10 |
2021-03-24 |
Арбутус Биофарма Корпорэйшн |
Липиды и композиции для доставки лекарственных средств
|
|
NZ593618A
(en)
|
2008-12-10 |
2013-02-22 |
Alnylam Pharmaceuticals Inc |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
|
US10292932B2
(en)
*
|
2008-12-26 |
2019-05-21 |
Samyang Biopharmaceuticals Corporation |
Polymeric micelle particle comprising anionic drugs and method of preparing the same
|
|
AU2009330859B2
(en)
*
|
2008-12-26 |
2013-06-20 |
Samyang Holdings Corporation |
Pharmaceutical composition containing an anionic drug, and a production method therefor
|
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
|
CA2750561C
(en)
|
2009-01-26 |
2017-10-10 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein c-iii expression
|
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
|
EP2669290A1
(en)
|
2009-03-02 |
2013-12-04 |
Alnylam Pharmaceuticals Inc. |
Nucleic Acid Chemical Modifications
|
|
CN102439151A
(zh)
|
2009-03-19 |
2012-05-02 |
默沙东公司 |
使用短干扰核酸（siNA）的RNA干扰介导的BTB和CNC同系物1，碱性亮氨酸拉链转录因子1（Bach1）基因表达的抑制
|
|
US20120035247A1
(en)
|
2009-03-19 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
US20120029054A1
(en)
|
2009-03-19 |
2012-02-02 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
|
|
JP2012520683A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
|
|
AU2010226434A1
(en)
*
|
2009-03-20 |
2011-10-13 |
Egen, Inc. |
Polyamine derivatives
|
|
JP2012521763A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子１（ＳＴＡＴ１）遺伝子発現のＲＮＡ干渉媒介性阻害
|
|
US20120010272A1
(en)
|
2009-03-27 |
2012-01-12 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
US20120022143A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
|
|
EP2411018A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
|
US20120004282A1
(en)
|
2009-03-27 |
2012-01-05 |
Merck Sharp & Dohme Corp, |
RNA Interference Mediated Inhibition of the Intercellular Adhesion Molecule 1 (ICAM-1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
|
AU2010245933B2
(en)
|
2009-05-05 |
2016-06-16 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
|
US9080186B2
(en)
*
|
2009-05-16 |
2015-07-14 |
Agave Pharma, Incorporated |
Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules
|
|
NZ597504A
(en)
*
|
2009-06-15 |
2013-10-25 |
Alnylam Pharmaceuticals Inc |
Lipid formulated dsrna targeting the pcsk9 gene
|
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
|
GB0910723D0
(en)
|
2009-06-22 |
2009-08-05 |
Sylentis Sau |
Novel drugs for inhibition of gene expression
|
|
WO2011000106A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Improved cationic lipids and methods for the delivery of therapeutic agents
|
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
|
CA2767129C
(en)
|
2009-07-01 |
2015-01-06 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
|
US9029338B2
(en)
|
2009-08-14 |
2015-05-12 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
|
HUE031793T2
(en)
*
|
2009-08-31 |
2017-07-28 |
Nanocarrier Co Ltd |
Particle composition and pharmaceutical composition containing such
|
|
US9187746B2
(en)
|
2009-09-22 |
2015-11-17 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting siRNA agents
|
|
EP2480668A2
(en)
|
2009-09-23 |
2012-08-01 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
DK3252068T3
(da)
|
2009-10-12 |
2025-08-25 |
Larry J Smith |
Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro
|
|
EP2496238A4
(en)
|
2009-11-03 |
2013-10-02 |
Alnylam Pharmaceuticals Inc |
FORMULATED LIPID COMPOSITIONS AND METHODS FOR INHIBITING TRANSTHYRETIN EXPRESSION (TTR)
|
|
KR101605932B1
(ko)
|
2009-12-18 |
2016-03-24 |
노파르티스 아게 |
Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물
|
|
WO2011091396A1
(en)
*
|
2010-01-25 |
2011-07-28 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mylip/idol gene
|
|
AU2011232365A1
(en)
|
2010-03-24 |
2012-10-25 |
Rxi Pharmaceuticals Corporation |
RNA interference in dermal and fibrotic indications
|
|
EP3578183B1
(en)
|
2010-03-24 |
2021-09-08 |
Phio Pharmaceuticals Corp. |
Rna interference in ocular indications
|
|
WO2011120023A1
(en)
|
2010-03-26 |
2011-09-29 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting survivin gene expression uses thereof
|
|
US8349308B2
(en)
|
2010-03-26 |
2013-01-08 |
Mersana Therapeutics, Inc. |
Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
|
|
ES2893199T3
(es)
|
2010-03-29 |
2022-02-08 |
Alnylam Pharmaceuticals Inc |
Terapia de ARNbc para amiloidosis ocular relacionada con transtiretina (TTR)
|
|
US8455455B1
(en)
|
2010-03-31 |
2013-06-04 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes involved in hemorrhagic fever
|
|
KR100986604B1
(ko)
*
|
2010-04-01 |
2010-10-08 |
충남대학교산학협력단 |
신규한 아미노지질을 함유하는 에스아이알엔에이 수송용 유전자 조성물 및 제조방법
|
|
EP4385568A3
(en)
|
2010-04-06 |
2025-02-12 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of cd274/pd-l1 gene
|
|
WO2011133584A2
(en)
|
2010-04-19 |
2011-10-27 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting hras gene expression and uses thereof
|
|
EA034363B1
(ru)
|
2010-04-23 |
2020-01-30 |
Эрроухед Фармасьютикалс, Инк. |
Фармацевтическая композиция для ингибирования экспрессии гена beta-enac и ее применение
|
|
WO2011139843A2
(en)
|
2010-04-28 |
2011-11-10 |
Marina Biotech, Inc. |
Multi-sirna compositions for reducing gene expression
|
|
EP2569276B1
(en)
|
2010-05-12 |
2021-02-24 |
Arbutus Biopharma Corporation |
Novel cationic lipids and methods of use thereof
|
|
US10077232B2
(en)
|
2010-05-12 |
2018-09-18 |
Arbutus Biopharma Corporation |
Cyclic cationic lipids and methods of use
|
|
KR101198715B1
(ko)
|
2010-05-14 |
2012-11-13 |
한국생명공학연구원 |
핵산 및 친수성 음이온 화합물의 고효율 포획을 위한 비대칭 리포솜 및 이의 제조방법
|
|
CA2801066C
(en)
|
2010-06-02 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
|
WO2012000104A1
(en)
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
PL3243526T3
(pl)
|
2010-07-06 |
2020-05-18 |
Glaxosmithkline Biologicals S.A. |
Dostarczanie rna w celu wyzwolenia wielu szlaków immunologicznych
|
|
PL2591114T3
(pl)
|
2010-07-06 |
2017-08-31 |
Glaxosmithkline Biologicals Sa |
Immunizacja dużych ssaków małymi dawkami rna
|
|
FI4005592T3
(fi)
|
2010-07-06 |
2023-01-13 |
|
Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
|
|
ES2557382T3
(es)
|
2010-07-06 |
2016-01-25 |
Glaxosmithkline Biologicals Sa |
Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
|
|
US9770463B2
(en)
*
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
|
US8518907B2
(en)
|
2010-08-02 |
2013-08-27 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
|
WO2012018881A2
(en)
*
|
2010-08-03 |
2012-02-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for the regulation of rna
|
|
EP2609198B8
(en)
|
2010-08-24 |
2018-03-28 |
Sirna Therapeutics, Inc. |
SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
|
|
US9233997B2
(en)
|
2010-08-26 |
2016-01-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
|
|
HUE061068T2
(hu)
|
2010-08-31 |
2023-05-28 |
Glaxosmithkline Biologicals Sa |
Pegilált liposzómák immunogént kódoló RNS szállítására
|
|
EP4098324A1
(en)
|
2010-10-11 |
2022-12-07 |
GlaxoSmithKline Biologicals S.A. |
Antigen delivery platforms
|
|
EP3327125B1
(en)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
|
EP2649182A4
(en)
|
2010-12-10 |
2015-05-06 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for increasing erythropoietin (epo) production
|
|
US9127275B2
(en)
|
2010-12-10 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
|
EP3674409A1
(en)
|
2011-03-29 |
2020-07-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of tmprss6 gene
|
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
|
US9011903B2
(en)
|
2011-06-08 |
2015-04-21 |
Nitto Denko Corporation |
Cationic lipids for therapeutic agent delivery formulations
|
|
AU2012272908A1
(en)
|
2011-06-21 |
2013-12-19 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
|
WO2012177949A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
|
JP6110372B2
(ja)
|
2011-06-21 |
2017-04-05 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
アンジオポエチン様３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物及びその使用方法
|
|
RU2631805C2
(ru)
|
2011-06-21 |
2017-09-26 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3)
|
|
US20140235693A1
(en)
|
2011-06-23 |
2014-08-21 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
|
WO2013019857A2
(en)
|
2011-08-01 |
2013-02-07 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
|
CN103930547A
(zh)
|
2011-09-02 |
2014-07-16 |
诺华股份有限公司 |
用于治疗hsf1相关疾病的有机组合物
|
|
EP2764007A4
(en)
*
|
2011-10-05 |
2015-05-06 |
Protiva Biotherapeutics Inc |
COMPOSITIONS AND METHODS FOR DISABLING ALDEHYDE DEHYDROGENASE
|
|
PE20142362A1
(es)
|
2011-11-18 |
2015-01-30 |
Alnylam Pharmaceuticals Inc |
Agentes de iarn, composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
|
|
US9061063B2
(en)
|
2011-12-07 |
2015-06-23 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
HK1205758A1
(en)
|
2012-01-09 |
2015-12-24 |
Novartis Ag |
Rnai agents to treat beta-catenin related diseases
|
|
SI2817287T1
(sl)
|
2012-02-24 |
2019-02-28 |
Arbutus Biopharma Corporation |
Trialkilni kationski lipidi in postopki za njihovo uporabo
|
|
DK2833869T3
(da)
*
|
2012-04-04 |
2021-02-01 |
Samyang Biopharmaceuticals |
Fremgangsmåde til fremstilling af en sammensætning til administration af et anionisk lægemiddel
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
|
MX2014013367A
(es)
|
2012-05-02 |
2014-12-08 |
Novartis Ag |
Composiciones organicas para tratar enfermedades relacionadas con kras.
|
|
CN104854242B
(zh)
|
2012-12-05 |
2018-03-16 |
阿尔尼拉姆医药品有限公司 |
PCSK9 iRNA组合物及其使用方法
|
|
US9687448B2
(en)
|
2012-12-07 |
2017-06-27 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid lipid particle formulations
|
|
EP4299741A3
(en)
|
2012-12-12 |
2024-02-28 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
US10227589B2
(en)
*
|
2013-01-28 |
2019-03-12 |
Council Of Scientific And Industrial Research |
Method for inhibiting tumor growth through RNA-interference using liposomally associated CDC20 siRNA
|
|
EP3845248A1
(en)
|
2013-02-05 |
2021-07-07 |
1Globe Health Institute LLC |
Biodegradable and clinically-compatible nanoparticles as drug delivery carriers
|
|
WO2014130922A1
(en)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
|
CA2902393C
(en)
|
2013-02-28 |
2022-11-01 |
Arrowhead Research Corporation |
Organic compositions to treat epas1-related diseases
|
|
EP2994167B1
(en)
|
2013-05-06 |
2020-05-06 |
Alnylam Pharmaceuticals, Inc. |
Dosages and methods for delivering lipid formulated nucleic acid molecules
|
|
TWI492751B
(zh)
*
|
2013-06-04 |
2015-07-21 |
Univ Kaohsiung Medical |
柴胡皂苷製備之醫藥組合物、其用途及其製備方法
|
|
EP3011031B1
(en)
|
2013-06-17 |
2020-09-30 |
The Broad Institute Inc. |
Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
|
|
KR20160056869A
(ko)
|
2013-06-17 |
2016-05-20 |
더 브로드 인스티튜트, 인코퍼레이티드 |
바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
|
|
ES2767318T3
(es)
|
2013-06-17 |
2020-06-17 |
Broad Inst Inc |
Suministro, modificación y optimización de sistemas, métodos y composiciones para generar modelos y actuar sobre enfermedades y trastornos de células posmitóticas
|
|
CN105555757A
(zh)
|
2013-07-23 |
2016-05-04 |
普洛体维生物治疗公司 |
用于递送信使rna的组合物和方法
|
|
US10077444B2
(en)
|
2013-10-02 |
2018-09-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
|
WO2015051135A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Organic compositions to treat hepcidin-related diseases
|
|
TWI694080B
(zh)
|
2013-10-04 |
2020-05-21 |
美國西奈山伊坎醫學院 |
抑制ａｌａｓ１基因表現的組合物及方法
|
|
WO2015074010A2
(en)
|
2013-11-18 |
2015-05-21 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for cardiac regeneration
|
|
JP6883987B2
(ja)
|
2013-12-04 |
2021-06-09 |
フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． |
化学修飾されたオリゴヌクレオチドを利用する創傷治癒の処置のための方法
|
|
CN106103705A
(zh)
|
2013-12-12 |
2016-11-09 |
布罗德研究所有限公司 |
核苷酸重复障碍中crispr‑cas系统的组合物和使用方法
|
|
CA2932479A1
(en)
|
2013-12-12 |
2015-06-18 |
The Rockefeller University |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
|
|
WO2015089473A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
KR20250068794A
(ko)
|
2013-12-12 |
2025-05-16 |
더 브로드 인스티튜트, 인코퍼레이티드 |
게놈 편집을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 용도 및 치료적 응용
|
|
WO2015089419A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
|
EP3137119B1
(en)
|
2014-04-28 |
2020-07-01 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using a nucleic acid targeting mdm2
|
|
CA2947619A1
(en)
|
2014-05-01 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
|
|
CN106536056B
(zh)
|
2014-06-13 |
2021-07-16 |
儿童医学中心公司 |
分离线粒体的产品和方法
|
|
HUE060907T2
(hu)
|
2014-06-25 |
2023-04-28 |
Acuitas Therapeutics Inc |
Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
|
|
WO2016011123A1
(en)
|
2014-07-16 |
2016-01-21 |
Arrowhead Research Corporation |
Organic compositions to treat apoc3-related diseases
|
|
WO2016028682A1
(en)
|
2014-08-17 |
2016-02-25 |
The Broad Institute Inc. |
Genome editing using cas9 nickases
|
|
DK3185957T3
(da)
|
2014-08-29 |
2022-08-29 |
Alnylam Pharmaceuticals Inc |
Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
|
|
KR102506169B1
(ko)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
|
US20180010132A1
(en)
|
2014-09-11 |
2018-01-11 |
Novartis Ag |
Inhibition of prmt5 to treat mtap-deficiency-related diseases
|
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
US10415037B2
(en)
|
2014-10-02 |
2019-09-17 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing hepatitis B virus gene expression
|
|
EP3227446A1
(en)
|
2014-12-01 |
2017-10-11 |
Novartis AG |
Compositions and methods for diagnosis and treatment of prostate cancer
|
|
WO2016094872A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
|
WO2016094867A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Protected guide rnas (pgrnas)
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
EP3234141A4
(en)
|
2014-12-18 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Reversir tm compounds
|
|
WO2016100974A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
WO2016106244A1
(en)
|
2014-12-24 |
2016-06-30 |
The Broad Institute Inc. |
Crispr having or associated with destabilization domains
|
|
EP3265060B1
(en)
*
|
2015-03-03 |
2020-10-21 |
Matinas BioPharma Nanotechnologies, Inc. |
Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent
|
|
CN104922141B
(zh)
*
|
2015-05-28 |
2016-05-25 |
厦门成坤生物技术有限公司 |
一种用于治疗乙型病毒性肝炎的siRNA组合物
|
|
US20180245074A1
(en)
|
2015-06-04 |
2018-08-30 |
Protiva Biotherapeutics, Inc. |
Treating hepatitis b virus infection using crispr
|
|
US20180296537A1
(en)
|
2015-06-05 |
2018-10-18 |
Novartis Ag |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
|
WO2016205745A2
(en)
*
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Cell sorting
|
|
FI3430134T3
(fi)
|
2015-06-18 |
2023-01-13 |
|
Uusia CRISPR-entsyymejä ja järjestelmiä
|
|
AU2016279062A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
KR102840885B1
(ko)
|
2015-06-18 |
2025-07-30 |
더 브로드 인스티튜트, 인코퍼레이티드 |
표적외 효과를 감소시키는 crispr 효소 돌연변이
|
|
US10221127B2
(en)
|
2015-06-29 |
2019-03-05 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
CA2991598A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
|
WO2017019891A2
(en)
|
2015-07-29 |
2017-02-02 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing hepatitis b virus gene expression
|
|
ES2842300T3
(es)
|
2015-07-31 |
2021-07-13 |
Alnylam Pharmaceuticals Inc |
Composiciones de ARNi de transtiretina (TTR) y métodos para su uso para el tratamiento o la prevención de enfermedades asociadas con TTR
|
|
US9856481B2
(en)
|
2015-08-13 |
2018-01-02 |
Ann & Robert H. Lurie Children's Hospital |
MicroRNA treatment of fibrosis
|
|
WO2017031370A1
(en)
|
2015-08-18 |
2017-02-23 |
The Broad Institute, Inc. |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
WO2017070151A1
(en)
|
2015-10-19 |
2017-04-27 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
|
|
KR20250021623A
(ko)
|
2015-10-22 |
2025-02-13 |
더 브로드 인스티튜트, 인코퍼레이티드 |
타입 vi-b crispr 효소 및 시스템
|
|
WO2017074788A1
(en)
|
2015-10-27 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
|
WO2018081480A1
(en)
|
2016-10-26 |
2018-05-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
IL307179A
(en)
|
2015-10-28 |
2023-11-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
EP3368689B1
(en)
|
2015-10-28 |
2020-06-17 |
The Broad Institute, Inc. |
Composition for modulating immune responses by use of immune cell gene signature
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017095944A1
(en)
|
2015-11-30 |
2017-06-08 |
Flagship Pioneering, Inc. |
Methods and compositions relating to chondrisomes from blood products
|
|
WO2017096326A1
(en)
|
2015-12-02 |
2017-06-08 |
Massachusetts Institute Of Technology |
Method for efficient generation of neurons from non-neuronal cells
|
|
US12110490B2
(en)
|
2015-12-18 |
2024-10-08 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
|
MA43870A
(fr)
|
2016-01-11 |
2021-05-26 |
Celator Pharmaceuticals Inc |
Inhibition de la protéine associée à l'ataxie télangiectasie et à rad3 (atr)
|
|
EP4653048A2
(en)
|
2016-01-15 |
2025-11-26 |
The Children's Medical Center Corporation |
Therapeutic use of mitochondria and combined mitochondrial agents
|
|
EP3445853A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
CA3026110A1
(en)
|
2016-04-19 |
2017-11-02 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
US12410416B2
(en)
|
2016-04-19 |
2025-09-09 |
The Broad Institute, Inc. |
CRISPR enzymes and systems with modified pam specificity
|
|
WO2017219027A1
(en)
|
2016-06-17 |
2017-12-21 |
The Broad Institute Inc. |
Type vi crispr orthologs and systems
|
|
WO2018005873A1
(en)
|
2016-06-29 |
2018-01-04 |
The Broad Institute Inc. |
Crispr-cas systems having destabilization domain
|
|
WO2018006052A1
(en)
|
2016-06-30 |
2018-01-04 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
|
EP4485466A3
(en)
|
2016-08-17 |
2025-04-02 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
CN110312799A
(zh)
|
2016-08-17 |
2019-10-08 |
博德研究所 |
新型crispr酶和系统
|
|
US20210284733A1
(en)
*
|
2016-08-22 |
2021-09-16 |
Arbutus Biopharma Corporation |
Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
|
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
WO2018047148A1
(en)
|
2016-09-12 |
2018-03-15 |
Novartis Ag |
Compounds for the inhibition of mirna
|
|
US12499971B2
(en)
|
2016-09-28 |
2025-12-16 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
EP3535396A1
(en)
|
2016-11-01 |
2019-09-11 |
Novartis AG |
Methods and compositions for enhancing gene editing
|
|
US10526284B2
(en)
*
|
2016-12-21 |
2020-01-07 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
|
JP2020511141A
(ja)
|
2017-03-15 |
2020-04-16 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
新規Ｃａｓ１３ｂオルソログＣＲＩＳＰＲ酵素及び系
|
|
JP7162021B2
(ja)
|
2017-03-17 |
2022-10-27 |
ニューカッスル ユニバーシティ |
筋ジストロフィーを治療するためのマイクロジストロフィン断片のアデノ随伴ウイルスベクター送達
|
|
KR20240155360A
(ko)
|
2017-04-12 |
2024-10-28 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규 타입 vi crispr 오르소로그 및 시스템
|
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
WO2018191750A2
(en)
|
2017-04-14 |
2018-10-18 |
The Broad Institute Inc. |
Novel delivery of large payloads
|
|
JP7167059B2
(ja)
|
2017-04-19 |
2022-11-08 |
フィオ ファーマシューティカルズ コーポレーション |
核酸化合物の局所送達
|
|
CN116693411A
(zh)
|
2017-04-28 |
2023-09-05 |
爱康泰生治疗公司 |
用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
|
|
US11591601B2
(en)
|
2017-05-05 |
2023-02-28 |
The Broad Institute, Inc. |
Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
|
|
BR112019023323A2
(pt)
|
2017-05-08 |
2020-07-21 |
Flagship Pioneering Innovations V, Inc. |
composições para facilitar a fusão de membrana e usos das mesmas
|
|
EP3625342B1
(en)
|
2017-05-18 |
2022-08-24 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
KR20200038236A
(ko)
|
2017-06-13 |
2020-04-10 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
큐론을 포함하는 조성물 및 그의 용도
|
|
EP4085919A3
(en)
|
2017-07-21 |
2023-02-08 |
Novartis AG |
Compositions and methods to treat cancer
|
|
US11639329B2
(en)
|
2017-08-16 |
2023-05-02 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US12065396B2
(en)
|
2017-08-17 |
2024-08-20 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
CN111315359A
(zh)
*
|
2017-08-31 |
2020-06-19 |
摩登纳特斯有限公司 |
制备脂质纳米颗粒的方法
|
|
US10597657B2
(en)
|
2017-09-11 |
2020-03-24 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
|
|
US11806360B2
(en)
|
2017-09-19 |
2023-11-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
|
|
CA3073848A1
(en)
|
2017-09-21 |
2019-03-28 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
EP3692152B1
(en)
|
2017-10-04 |
2025-09-03 |
The Broad Institute, Inc. |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
|
US12227742B2
(en)
|
2017-10-23 |
2025-02-18 |
The Broad Institute, Inc. |
Nucleic acid modifiers
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
WO2019089803A1
(en)
|
2017-10-31 |
2019-05-09 |
The Broad Institute, Inc. |
Methods and compositions for studying cell evolution
|
|
EP3707278A1
(en)
|
2017-11-09 |
2020-09-16 |
Alnylam Pharmaceuticals Inc. |
Assays and methods for determining expression of the lect2 gene
|
|
US12018080B2
(en)
|
2017-11-13 |
2024-06-25 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway
|
|
WO2019118806A1
(en)
|
2017-12-14 |
2019-06-20 |
Solid Biosciences Inc. |
Non-viral production and delivery of genes
|
|
US11021692B2
(en)
|
2017-12-19 |
2021-06-01 |
Janssen Sciences Ireland Unlimited Company |
Hepatitis B virus (HBV) vaccines and uses thereof
|
|
EP3728575A4
(en)
|
2017-12-22 |
2021-11-24 |
The Broad Institute, Inc. |
CAS12B SYSTEMS, METHODS AND COMPOSITIONS FOR SPECIFIC EDITING OF DNA BASES
|
|
TWI802627B
(zh)
|
2017-12-28 |
2023-05-21 |
日商武田藥品工業股份有限公司 |
陽離子性脂質
|
|
US12031130B2
(en)
|
2017-12-28 |
2024-07-09 |
Takeda Pharmaceutical Company Limited |
Composition for modifying target gene
|
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
|
US20210123016A1
(en)
|
2018-05-02 |
2021-04-29 |
Novartis Ag |
Regulators of human pluripotent stem cells and uses thereof
|
|
KR20190127277A
(ko)
*
|
2018-05-04 |
2019-11-13 |
주식회사 삼양바이오팜 |
mRNA 전달용 고분자 나노입자 조성물 및 그 제조방법
|
|
JP7646362B2
(ja)
|
2018-06-18 |
2025-03-17 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクターデリバリー
|
|
WO2020033601A1
(en)
|
2018-08-07 |
2020-02-13 |
The Broad Institute, Inc. |
Novel cas12b enzymes and systems
|
|
WO2020037125A1
(en)
|
2018-08-16 |
2020-02-20 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
WO2020041380A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
US12329857B2
(en)
|
2018-09-21 |
2025-06-17 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
EP3856146A4
(en)
*
|
2018-09-28 |
2022-07-06 |
Nutcracker Therapeutics, Inc. |
Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
|
|
PT3864163T
(pt)
|
2018-10-09 |
2024-04-30 |
Univ British Columbia |
Composições e sistemas que compreendem vesículas competentes para transfeção isentas de solventes orgânicos e detergentes e métodos relacionados com as mesmas
|
|
UA130104C2
(uk)
|
2018-11-09 |
2025-11-12 |
Арбутус Біофарма Корпорейшн |
Композиції на основі ліпідних наночастинок
|
|
WO2020097493A1
(en)
*
|
2018-11-09 |
2020-05-14 |
Arbutus Biopharma Corporation |
Negatively charged peg-lipid conjugates
|
|
US12350383B2
(en)
*
|
2018-11-09 |
2025-07-08 |
Arbutus Biopharma Corporation |
Cationic lipids containing silicon
|
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
|
HRP20231338T1
(hr)
|
2018-12-20 |
2024-02-16 |
Vir Biotechnology, Inc. |
Kombinirana terapija hbv
|
|
MX2021008261A
(es)
|
2019-01-09 |
2021-08-16 |
Arrowhead Pharmaceuticals Inc |
Agentes de rnai para inhibir la expresion de hif-2 a (epas1), composiciones de estos y metodos de uso.
|
|
AU2020205717B2
(en)
|
2019-01-11 |
2025-09-11 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
US20220177863A1
(en)
|
2019-03-18 |
2022-06-09 |
The Broad Institute, Inc. |
Type vii crispr proteins and systems
|
|
US20220220469A1
(en)
|
2019-05-20 |
2022-07-14 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
|
AU2020295796A1
(en)
|
2019-06-18 |
2022-02-10 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis B virus (HBV) vaccines and HBV-targeting rnai
|
|
WO2020255010A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
|
|
US20250041386A1
(en)
|
2019-06-18 |
2025-02-06 |
Janssen Sciences Ireland Unlimited Company |
Recombinant Interleukin 12 Construct and Uses Thereof
|
|
KR20220041079A
(ko)
|
2019-06-18 |
2022-03-31 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
B형 간염 바이러스(hbv) 백신 및 항-pd-1 항체의 조합
|
|
EP3986454A1
(en)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
|
EP3986563A1
(en)
*
|
2019-06-20 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
|
|
CN114901253A
(zh)
|
2019-08-14 |
2022-08-12 |
爱康泰生治疗公司 |
用于递送核酸的改进的脂质纳米颗粒
|
|
MX2022002689A
(es)
|
2019-09-03 |
2022-04-07 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen de quimiotaxina derivada de celulas de leucocitos 2 (lect2).
|
|
US12503699B2
(en)
|
2019-10-04 |
2025-12-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing UGT1a1 gene expression
|
|
EP4051796A1
(en)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
CN115135765A
(zh)
|
2019-11-08 |
2022-09-30 |
菲奥医药公司 |
用于免疫治疗的靶向含布罗莫结构域之蛋白4(brd4)的经化学修饰的寡核苷酸
|
|
WO2021138537A1
(en)
|
2019-12-31 |
2021-07-08 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides with improved systemic delivery
|
|
WO2021163066A1
(en)
|
2020-02-10 |
2021-08-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing vegf-a expression
|
|
WO2021188389A2
(en)
|
2020-03-17 |
2021-09-23 |
Genevant Sciences Gmbh |
Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
|
|
EP4127171A2
(en)
|
2020-03-30 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
KR20220161316A
(ko)
|
2020-03-30 |
2022-12-06 |
비온테크 에스이 |
Claudin-18.2를 표적화하는 rna 조성물
|
|
WO2021207167A1
(en)
|
2020-04-06 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
|
WO2021207189A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
|
CN111494641B
(zh)
*
|
2020-04-22 |
2021-08-03 |
南开大学 |
肿瘤微环境响应性的表面电荷可反转纳米药物递送载体
|
|
US20230183707A1
(en)
|
2020-05-21 |
2023-06-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
WO2021257595A1
(en)
|
2020-06-15 |
2021-12-23 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery for muscular dystrophies
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
CN116390943A
(zh)
|
2020-06-24 |
2023-07-04 |
维尔生物科技有限公司 |
工程化乙型肝炎病毒中和抗体和其用途
|
|
EP4178613A1
(en)
|
2020-07-08 |
2023-05-17 |
Janssen Sciences Ireland Unlimited Company |
Rna replicon vaccines against hbv
|
|
AU2021308681A1
(en)
|
2020-07-16 |
2023-03-09 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
|
WO2022081750A1
(en)
|
2020-10-14 |
2022-04-21 |
George Mason Research Foundation, Inc. |
Ionizable lipids and methods of manufacture and use thereof
|
|
US11771652B2
(en)
|
2020-11-06 |
2023-10-03 |
Sanofi |
Lipid nanoparticles for delivering mRNA vaccines
|
|
MX2023006056A
(es)
|
2020-11-25 |
2023-06-06 |
Akagera Medicines Inc |
Nanoparticulas lipidicas para suministro de acidos nucleicos y metodos de uso de las mismas.
|
|
WO2022133230A1
(en)
|
2020-12-18 |
2022-06-23 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
|
US20240148663A1
(en)
|
2020-12-18 |
2024-05-09 |
Genevant Sciences Gmbh |
Peg lipids and lipid nanoparticles
|
|
EP4268851A4
(en)
*
|
2020-12-24 |
2024-12-11 |
EnhancedBio Inc. |
COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER, CONTAINING LIPID NANOPARTICLES
|
|
WO2022146654A1
(en)
|
2020-12-28 |
2022-07-07 |
Janssen Pharmaceuticals, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
|
WO2022215036A1
(en)
|
2021-04-08 |
2022-10-13 |
Vaxthera Sas |
Coronavirus vaccine comprising a mosaic protein
|
|
WO2022261394A1
(en)
|
2021-06-11 |
2022-12-15 |
LifeEDIT Therapeutics, Inc. |
Rna polymerase iii promoters and methods of use
|
|
JP2024528697A
(ja)
|
2021-07-20 |
2024-07-30 |
エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ |
微細藻類由来の細胞外小胞、その調製および使用
|
|
AR126675A1
(es)
|
2021-08-03 |
2023-11-01 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi CONTRA LA TRANSTIRRETINA (TTR) Y SUS MÉTODOS DE USO
|
|
JP2024529025A
(ja)
|
2021-08-04 |
2024-08-01 |
フィオ ファーマシューティカルズ コーポレーション |
化学修飾されたオリゴヌクレオチド
|
|
WO2023015264A1
(en)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
AU2022339821A1
(en)
|
2021-08-31 |
2024-03-07 |
Alnylam Pharmaceuticals, Inc. |
Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof
|
|
TW202325263A
(zh)
|
2021-09-14 |
2023-07-01 |
美商雷納嘉德醫療管理公司 |
非環狀脂質及其使用方法
|
|
CA3232386A1
(en)
|
2021-09-14 |
2023-03-23 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and methods of use thereof
|
|
CN118660710A
(zh)
|
2021-10-20 |
2024-09-17 |
罗切斯特大学 |
用于年龄相关白质损失的竞争性治疗的分离神经胶质祖细胞
|
|
EP4426832A1
(en)
|
2021-11-03 |
2024-09-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Precise genome editing using retrons
|
|
AU2022394985A1
(en)
|
2021-11-16 |
2024-05-30 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
EP4436549A1
(en)
|
2021-11-22 |
2024-10-02 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
KR20240123832A
(ko)
|
2021-12-16 |
2024-08-14 |
아퀴타스 테라퓨틱스 인크. |
지질 나노입자 제형에 사용하기 위한 지질
|
|
CA3243054A1
(en)
|
2021-12-23 |
2025-04-08 |
Renagade Therapeutics Management Inc. |
Constrained Lipids and Associated Utilization Processes
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
CA3242744A1
(en)
|
2022-01-27 |
2023-08-03 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
WO2023144127A1
(en)
|
2022-01-31 |
2023-08-03 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
|
|
EP4466250B1
(en)
|
2022-01-31 |
2025-03-26 |
Genevant Sciences Gmbh |
Ionizable cationic lipids for lipid nanoparticles
|
|
CN119072464A
(zh)
|
2022-03-25 |
2024-12-03 |
赛欧生物医药股份有限公司 |
新型可电离脂质和脂质纳米颗粒以及其使用方法
|
|
AU2023250649A1
(en)
|
2022-04-04 |
2024-11-14 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
|
CA3255619A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
|
|
KR20250007577A
(ko)
|
2022-04-27 |
2025-01-14 |
상하이 레제네리드 테라피즈 컴퍼니 리미티드 |
핵산 작제물 및 이의 응용
|
|
US20250346905A1
(en)
|
2022-05-05 |
2025-11-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
INTERFERING RNA THERAPY FOR PLN-R14del CARDIOMYOPATHY
|
|
JP2025516674A
(ja)
|
2022-05-13 |
2025-05-30 |
ビオンテック エスエー |
Ｈｉｖを標的とするｒｎａ組成物
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
CA3253047A1
(en)
|
2022-05-13 |
2025-07-04 |
Shanghai Regenelead Therapies Co., Ltd |
CONSTRUCTION OF NUCLEIC ACIDS INCLUDING A UTR AND ITS USE
|
|
WO2023230587A2
(en)
|
2022-05-25 |
2023-11-30 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
|
IL316504A
(en)
|
2022-05-25 |
2024-12-01 |
BioNTech SE |
RNA compositions for the delivery of monkeypox antigens and related methods
|
|
WO2023229535A1
(en)
|
2022-05-27 |
2023-11-30 |
Engine Biosciences Pte. Ltd. |
Bet polypeptide therapeutic agents for generating synthetic lethality in tumors
|
|
JP2025518221A
(ja)
|
2022-05-30 |
2025-06-12 |
ビオンテック・ソシエタス・エウロパエア |
核酸の送達のための複合体
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
WO2023232976A1
(en)
|
2022-06-03 |
2023-12-07 |
Ags Therapeutics Sas |
Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
|
|
CN117582417A
(zh)
*
|
2022-08-09 |
2024-02-23 |
湖南健瑞医药科技有限公司 |
药物-脂质颗粒及其制备方法和应用
|
|
KR20250058785A
(ko)
|
2022-08-12 |
2025-04-30 |
라이프 에디트 테라퓨틱스, 인크. |
Rna-가이드된 뉴클레아제 및 그의 활성 단편 및 변이체 및 사용 방법
|
|
AU2023334610A1
(en)
|
2022-08-31 |
2025-03-13 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
JP2025533527A
(ja)
|
2022-09-23 |
2025-10-07 |
ビオンテック・ソシエタス・エウロパエア |
Ｐｌａｓｍｏｄｉｕｍ ＣＳＰ抗原の送達のための組成物及び関連方法
|
|
JP2025533541A
(ja)
|
2022-09-23 |
2025-10-07 |
ビオンテック・ソシエタス・エウロパエア |
肝病期抗原の送達のための組成物及び関連方法
|
|
IL319682A
(en)
|
2022-10-06 |
2025-05-01 |
BioNTech SE |
RNA complexes targeting claudin-18.2
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
JP2025535944A
(ja)
|
2022-10-24 |
2025-10-30 |
エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ |
微細藻類由来の細胞外小胞、鼻腔内投与時のそれらの生体内分布、及びそれらの使用
|
|
WO2024141955A1
(en)
|
2022-12-28 |
2024-07-04 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2024158825A2
(en)
|
2023-01-23 |
2024-08-02 |
Engine Biosciences Pte. Ltd. |
Methods to modulate tau for treatment of tauopathies
|
|
AR131799A1
(es)
|
2023-02-09 |
2025-04-30 |
Alnylam Pharmaceuticals Inc |
Moléculas de reversir y métodos para su uso
|
|
WO2024220653A1
(en)
|
2023-04-19 |
2024-10-24 |
Gradalis, Inc. |
Compositions and methods for modulating sialic acid production and treating hereditary inclusion body myopathy (hibm)
|
|
WO2024229309A2
(en)
|
2023-05-03 |
2024-11-07 |
Manifold Biotechnologies, Inc. |
Methodsand compositions for high-throughput protein delivery, screening, and detection
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
AU2024265158A1
(en)
|
2023-05-03 |
2025-11-06 |
BioNTech SE |
Optimized csp variants and related methods
|
|
WO2024249954A1
(en)
|
2023-05-31 |
2024-12-05 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024335A2
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024337A1
(en)
|
2023-07-24 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025022367A2
(en)
|
2023-07-27 |
2025-01-30 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
WO2025027089A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thiolipids and uses thereof
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
WO2025030097A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
WO2025027576A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025052278A1
(en)
|
2023-09-05 |
2025-03-13 |
Genevant Sciences Gmbh |
Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
WO2025057088A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
WO2025072383A1
(en)
|
2023-09-25 |
2025-04-03 |
The Broad Institute, Inc. |
Viral open reading frames, uses thereof, and methods of detecting the same
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025083619A1
(en)
|
2023-10-18 |
2025-04-24 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and acive fragments and variants thereof and methods of use
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025129158A1
(en)
|
2023-12-15 |
2025-06-19 |
The Broad Institute, Inc. |
Engineered arc delivery vesicles and uses thereof
|
|
WO2025129201A1
(en)
|
2023-12-15 |
2025-06-19 |
Capstan Therapeutics, Inc. |
Humanized anti-cd8 antibodies and uses thereof
|
|
WO2025134062A2
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025166323A2
(en)
|
2024-02-02 |
2025-08-07 |
Editas Medicine, Inc. |
Crispr-related methods and compositions targeting lipoprotein (a) expression
|
|
WO2025174908A1
(en)
|
2024-02-12 |
2025-08-21 |
Life Edit Therapeutics, Inc. |
Novel rna-guided nucleases and proteins for polymerase editing
|
|
WO2025176847A1
(en)
|
2024-02-21 |
2025-08-28 |
Ags Therapeutics Sas |
Ocular delivery of active agents via microalgae extracellular vesicles
|
|
WO2025184508A1
(en)
|
2024-03-01 |
2025-09-04 |
Acuitas Therapeutics, Inc. |
Materials and methods for encapsulating therapeutics in lipid nanoparticles
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2025250808A1
(en)
|
2024-05-29 |
2025-12-04 |
The Brigham And Women’S Hospital, Inc. |
Anti-crispr delivery compositions and methods
|